About seller
f CAR-T cells and combined with HSCT after infusion are independent factors for improving the prognosis of the patients.Anti-cluster of classification (CD) 19 CAR-T cell therapy is safe and efficacious against relapsed or refractory B-ALL in children. Reducing the tumor burden before infusion of CAR-T cells and combined with HSCT after infusion are independent factors for improving the prognosis of the patients. To explore the influence of nm23-H1 on the proliferation and apoptosis of glioma cells and the mechanism of action. The changes in the messenger RNA (mRNA) expression of nm23-H1 were detected via quantitative real-time-polymerase chain reaction (qRT-PCR), and the relative protein expression level of nm23-H1 was determined using immunohistochemistry. The glioma H4 cells were transfected exogenously with nm23-H1 gene (nm23-H1 group) or empty vector (Vector group), and the biological influence of the expression level of nm23-H1 on H4 cells was then assessed through in vitro functional experiments. Besides, the cells transfected with nm23-H1 were incubated with the protein kinase C (PKC) pathway inhibitor Calphostin C, and functional experiments were performed to observe the changes in the proliferation and apoptosis of cells after incubation. According to the immunohistochemistry and qRT-PCR results, the protein and mRNA expression levels of nm23-H1 declined notably in glioma tissues (p<0.01). The cells with up-regulated nm23-H1 expression had substantially weakened proliferation and migration abilities, but exhibited dramatically enhanced apoptosis (p<0.01). The PKC pathway inhibitor considerably potentiated the effects of nm23-H1 protein on the proliferation and apoptosis of H4 cells (p<0.05), and the protein expression level of nm23-H1 rose in the cells treated with the PKC inhibitor (p<0.01). Compared with normal brain tissues, nm23-H1 is lowly expressed in glioma tissues and affects the expression of PKC to influence the biological behaviors of H4 cells.Compared with normal brain tissues, nm23-H1 is lowly expressed in glioma tissues and affects the expression of PKC to influence the biological behaviors of H4 cells. To explore the clinical efficacy and safety of bevacizumab combined with temozolomide dose-dense regimen in the treatment of recurrent glioma. The clinical data of 102 patients with recurrent glioma after surgery, radiotherapy or chemotherapy treated in our hospital from March 2016 to December 2018 were retrospectively analyzed. selleck inhibitor There were 51 patients undergoing bevacizumab combined with temozolomide treatment (Bevacizumab group), and the remaining 51 patients received temozolomide treatment alone (Control group). The clinical data of all patients were collected, the short-term efficacy, adverse reactions after treatment and quality of life score were compared between the two groups, and the levels of serum immune factors were recorded. The patients were followed up, and the overall survival (OS) rate and progression-free survival (PFS) rate were recorded. All patients underwent bevacizumab treatment for 2-12 cycles, with an average of 6.3 cycles. The objective response rate (ORR) was 47.1% (24/51) and ificantly improve the clinical efficacy, increase the quality of life of patients, and delay the progression of recurrent glioma, with tolerable adverse reactions.Bevacizumab combined with temozolomide can significantly improve the clinical efficacy, increase the quality of life of patients, and delay the progression of recurrent glioma, with tolerable adverse reactions. To explore the efficacy and safety of cetuximab combined with intensity-modulated radiotherapy (IMRT) and concurrent cisplatin-based chemotherapy in the treatment of patients with locally advanced nasopharyngeal carcinoma. The clinical information of 126 patients with locally advanced nasopharyngeal carcinoma, who were admitted to and treated in our department from September 2013 to May 2016, was collected, and they were randomly divided into two groups cetuximab combined with IMRT and concurrent cisplatin-based chemotherapy group (Cetuximab group, n=63) and IMRT combined with concurrent cisplatin-based chemotherapy group (Control group, n=63). The clinical efficacy, changes in patients' quality of life and incidence of adverse reactions were observed and compared between the two groups, and the tumor progression and survival of the patients were followed up and recorded. The patients in Cetuximab group exhibited substantially higher objective remission rate (ORR) and disease control rate (DCR) [90.5% (combined with IMRT and concurrent cisplatin-based chemotherapy has better clinical short-term efficacy in treating locally advanced nasopharyngeal carcinoma, and the patients treated have improved quality of life and can tolerate adverse reactions.Cetuximab combined with IMRT and concurrent cisplatin-based chemotherapy has better clinical short-term efficacy in treating locally advanced nasopharyngeal carcinoma, and the patients treated have improved quality of life and can tolerate adverse reactions. We aimed to explore the efficacy of low-temperature plasma ablation (LTPA) combined with low-dose cisplatin chemotherapy in laryngeal carcinoma patients and its influence on tumor markers. A total of 86 patients with laryngeal carcinoma were selected and divided into control group (n=43, treated with routine chemotherapy) and observation group (n=43, treated with LTPA combined with low-dose cisplatin chemotherapy) according to different treatment methods. The efficacy, immune function, adverse reactions and tumor marker levels were assessed in both groups, and the survival rate of patients was compared between the two groups. The objective response rate and disease control rate in the observation group were significantly higher than those in the control group (p<0.05). After treatment, the observation group had higher levels of cluster of differentiation (CD)3+, CD4+ and CD4+/CD8+ than the control group, and a lower level of CD8+ than the control group (p<0.05). At 4, 8 and 16 weeks after treatmenon. To analyze the role of lncRNA LSINCT5 in oral squamous cell carcinoma (OSCC) progression and the molecular mechanism. QRT-PCR was conducted to detect LSINCT5 levels in OSCC tissues and cell lines. Survival analysis in OSCC patients based on LSINCT5 levels was performed using Kaplan-Meier method. Influence of LSINCT5 on functions of OSCC cells were assessed by CCK-8, EdU and Transwell assay. Bioinformatic analysis and dual-luciferase reporter assay were carried out to identify the interaction between LSINCT5 and the miRNA (miR)-185-5p/zNF703 axis. Rescue experiments were conducted to uncover the molecular mechanism of LSINCT5 in regulating OSCC cell functions. LSINCT5 was upregulated in OSCC specimens and correlated to poor prognosis of OSCC. Knockdown of LSINCT5 inhibited proliferative and migratory capacities of OSCC. LSINCT5 could target and negatively regulate miR-185-5p. Moreover, miR-185-5p was the key downstream gene that was responsible for the carcinogenic role of LSINCT5 in regulating OSCC cell functions.